Structure Therapeutics Inc. American Depositary Shares (GPCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has a cash flow conversion efficiency ratio of 0.011x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.28 Million) by net assets ($1.45 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GPCR net asset quality index to measure how much of total assets are equity-financed.
Structure Therapeutics Inc. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Structure Therapeutics Inc. American Dep's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Structure Therapeutics Inc. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Film Co Ltd
SHG:600977
|
0.059x |
|
Hangzhou EZVIZ Network Co. Ltd. A
SHG:688475
|
N/A |
|
Ventia Services Group Ltd
AU:VNT
|
0.348x |
|
AP Memory Technology Corp
TW:6531
|
0.051x |
|
Stride Inc
NYSE:LRN
|
0.135x |
|
Golub Capital BDC Inc
NASDAQ:GBDC
|
0.067x |
|
Qingdao East Steel Tower Stock Co Ltd
SHE:002545
|
0.055x |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
0.008x |
Annual Cash Flow Conversion Efficiency for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Structure Therapeutics Inc. American Dep market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.52 Billion | $-222.20 Million | -0.147x | -8.65% |
| 2024-12-31 | $864.84 Million | $-116.64 Million | -0.135x | +23.15% |
| 2023-12-31 | $452.97 Million | $-79.49 Million | -0.175x | -143.81% |
| 2022-12-31 | $-115.14 Million | $-46.12 Million | 0.401x | -19.37% |
| 2021-12-31 | $-64.73 Million | $-32.16 Million | 0.497x | -21.85% |
| 2020-12-31 | $-22.47 Million | $-14.28 Million | 0.636x | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more